PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC) (Q33688849)

28 July 2017

title

PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC) (English)

1 reference

28 July 2017

Liyan Jiang

1

1 reference

28 July 2017

Xinying Su

2

1 reference

28 July 2017

Tianwei Zhang

3

1 reference

28 July 2017

Xiaolu Yin

4

1 reference

28 July 2017

Meizhuo Zhang

5

1 reference

28 July 2017

Haihua Fu

6

1 reference

28 July 2017

Hulin Han

7

1 reference

28 July 2017

Yun Sun

8

1 reference

28 July 2017

Lili Dong

9

1 reference

28 July 2017

Jialin Qian

10

1 reference

28 July 2017

Yanhua Xu

11

1 reference

28 July 2017

Xuan Fu

12

1 reference

28 July 2017

Paul R Gavine

13

1 reference

28 July 2017

Yanbin Zhou

14

1 reference

28 July 2017

Kun Tian

15

1 reference

28 July 2017

Jiaqi Huang

16

1 reference

28 July 2017

Dong Shen

17

1 reference

28 July 2017

Haiyi Jiang

18

1 reference

28 July 2017

Yihong Yao

19

1 reference

28 July 2017

Baohui Han

20

1 reference

28 July 2017

Yi Gu

21

1 reference

28 July 2017

language of work or name

English

0 references

publication date

1 April 2017

1 reference

28 July 2017

1 reference

28 July 2017

volume

8

1 reference

28 July 2017

issue

16

1 reference

28 July 2017

page(s)

26845-26857

1 reference

Clinical and Molecular Characteristics of NF1-Mutant Lung Cancer.

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

Impact of smoking on mortality of patients with non-small cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

PD-L1 is remarkably over-expressed in EBV-associated pulmonary lymphoepithelioma-like carcinoma and related to poor disease-free survival

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

PD-1 and PD-L1 Expression in NSCLC Indicate a Favorable Prognosis in Defined Subgroups

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

Association of PDCD1 and CTLA-4 Gene Expression with Clinicopathological Factors and Survival in Non-Small-Cell Lung Cancer: Results from a Large and Pooled Microarray Database

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

PD-L1 expression is a favorable prognostic factor in early stage non-small cell carcinoma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

Classifying Cancers Based on T-cell Infiltration and PD-L1.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

Clinicopathological and prognostic significance of programmed cell death ligand1 (PD-L1) expression in patients with non-small cell lung cancer: a meta-analysis

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

The association between PD-L1 and EGFR status and the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

Pembrolizumab for the treatment of non-small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

The prognostic value of PD-L1 expression for non-small cell lung cancer patients: a meta-analysis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

PD-1 blockade induces responses by inhibiting adaptive immune resistance

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

Programmed cell death-ligand 1 expression in surgically resected stage I pulmonary adenocarcinoma and its correlation with driver mutations and clinical outcomes.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

FGFR2 amplification has prognostic significance in gastric cancer: results from a large international multicentre study

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

Programmed death ligand-1 expression in non-small cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

Relationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patients

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

Identifying and targeting ROS1 gene fusions in non-small cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

The blockade of immune checkpoints in cancer immunotherapy

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

The immune contexture in human tumours: impact on clinical outcome

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

Cancer immunotherapy comes of age

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

EML4-ALK rearrangement in non-small cell lung cancer and non-tumor lung tissues

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

Non-small cell lung cancer, version 1.2015.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

Breakthrough of the year 2013. Cancer immunotherapy

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5432301

Clinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up study

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28460468

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/28460468

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.18632/ONCOTARGET.15839

1 reference

28 July 2017

1 reference

28 July 2017

1 reference